AIRTO member Lucideon has announced the launch of its new, dedicated biocompatibility laboratory in the United States, complementing existing UK capabilities, significantly advancing its global testing infrastructure for materials and medical devices
The laboratory will enable Lucideon to offer more rapid and robust assessments of medical materials’ interactions with human biological systems, ensuring patient safety and helping device manufacturers meet strict regulatory requirements.
What the new lab offers:
- Comprehensive testing: The facility enhances Lucideon’s existing capabilities of direct toxicity, but also more complex interactions such as effects on surrounding tissues, potential for immune response, and performance over time.
- Faster turnaround: Locally based in the U.S., the lab removes delays related to overseas shipping of materials for testing, enabling quicker feedback to manufacturers.
- Regulatory alignment: The laboratory’s protocols are designed to conform with U.S. FDA requirements and international standards, a critical factor for devices seeking approval in multiple markets.
